MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-19-2026
Akari Therapeutics, Plc ROA Ratio 2011-2026 | AKTX
Annual ROA Ratio Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.12 | -39.14 | -229.8 | -173.83 | -149.59 | -116.96 | -247.67 | -205.08 | -121.86 | -39.55 | -64.84 | -148.89 | -46.22 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -36.12 | -247.67 | -124.58 |
Quarterly ROA Ratio Akari Therapeutics, Plc
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | 2007-Q4 | 2006-Q4 | 2005-Q4 | 2004-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.75 | -130.99 | -265.78 | -462.85 | -455.58 | -545.57 | -433.01 | -335.6 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -134.8 | -173.49 | -83.5 | -83.5 | -111.57 | -247.19 | -197.98 | -159.29 | -206.15 | -179.08 | -61.32 | -59.05 | -59.05 | -63.79 | -16.93 | -16.93 | -16.93 | -78.49 | -77.49 | -77.49 | -77.49 | -122.79 | -114.02 | -109.28 | -115.85 | -88.69 | -192.29 | -189.86 | -6.57 | -34.4 | -148.89 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -6.57 | -545.57 | -150.3 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.02 | -0.98 % | $ 189 M |  Israel |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.42 | - | $ 166 M |  USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-142.36 | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-8.47 | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
20.2 | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 51.48 | -0.23 % | $ 4.63 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 29.6 | 3.64 % | $ 1.97 B | USA |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 14.57 | -0.21 % | $ 209 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.91 | -5.52 % | $ 4.79 M | Israel |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 22.79 | 5.8 % | $ 2.9 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.82 | - | 3.16 % | $ 1.9 M | USA |